Alveonix Information

Alveonix is a Swiss pharmaceutical company focused on developing small molecules targeting the cold and menthol receptor TRPM8, which plays a critical role in sensory disorders such as itch, irritation, and pain. Alveonix’s proprietary technology platform has designed two families of specific long-lasting TRPM8 agonists to address large markets across a broad spectrum of opportunities such as dry eyes, cough, nasal congestion, non-erosive reflux disease, colitis, and pruritus. Alveonix’s s strategy is to develop its two lead molecules up-to phase II, to optimize value creation, in order to out license these assets to Pharmaceutical Companies to bring them to market as prescription drugs. For the dry eye indication, Alveonix beneficiates of strong clinical proof of concepts and of the support of Ora, the world’s leading independent, full-service ophthalmic clinical research and product development firm. AxAlveo, Alveonix’s subsidiary, develops molecules for the cough indication, through an existing strategic alliance with Develco. WE WELCOME INDIVIDUAL INVESTORS, PRIVATE EQUITY FIRMS, AND VC's TO CONTACT US DIRECTLY FOR FURTHER DETAILS.